. Author manuscript; available in PMC: 2011 Mar 2.

Published in final edited form as: Curr Med Res Opin. 2010 Nov 18;27(1):55–62. doi: 10.1185/03007995.2010.535511

Table 4.

Results of regression models comparing the three ZA-persistence groups.

	Log of FUP: coefficient (SE) from multiple regression	Time to first SC: HR (95% CI) from Cox regression	No. of SCs: coefficient (SE) from Poisson regression
Age	0.002 (0.005)	0.988 (0.963–1.013)	−0.004 (0.014)
CCI score	−0.092 (0.060)	1.157 (0.843–1.589)	0.092 (0.173)
Docetaxel treatment	0.421 (0.100)^*	1.458 (0.881–2.412)	0.147 (0.270)
Short ZA persistence	−0.819 (0.114)^*	0.683 (0.382–1.222)	−0.280 (0.315)
Medium ZA persistence	−0.510 (0.126)^*	0.551 (0.273–1.112)	−0.284 (0.342)

p<0.0001.

CCI, Charlson Comorbidity Index; CI, confidence interval; FUP, follow-up duration; HR, hazard ratio; SC, skeletal complications; SE, standard error; ZA, zoledronic acid.